BRAF gene mutation is a common mutation type in CRC, and a combination therapy strategy for MAPK pathway blockade brings hope for the treatment of metastatic CRC patients with BRAF v600e mutation [39,40,41,42]. Here, BRAF is linked to colorectal carcinoma.